WEBINAR

Accelerating Peptide Development: Strategies to optimize the formulation and manufacture of peptide therapeutics

Register here

Search

23 results for "Candidate Selection"

From candidate selection through to proof-of-concept

Building a robust understanding of your API characteristics matched against your development programme goals, supports the efficient transition of drug products from candidate selection through to proof-of-concept. Starting @ 4pm (BST-UK), 11pm (ET), 8am (PT) and 6pm (BST-UK), 1pm (ET), 10am (PT)

Candidate Selection

Drug Product Strategies to Accelerate from Candidate Selection to Proof-of-Concept

This webinar will summarise how a fully integrated development plan can bring together the needs of the drug product team and the clinical development team.

The Integration of Drug Substance and Drug Product

This webinar highlights how a fully integrated program can speed up transition from candidate selection to proof of concept and shorten the pathway to clinical development.

Drug Substance

Pharmaceutical CDMO & CRO | Quotient Sciences

At a glance

Pre-formulation screening

Pre-formulation screening

Pre-formulation screening

Oncology

Project Management at Quotient Sciences

Quotient is an innovative drug development and manufacturing partner supporting clients from candidate selection to commercial launch. With expertise in end-to-end Project Management and integrated project teams, we make drug development easier for our customers and dramatically reduce the time and cost of getting new medicines to patients.

Biopharm America 2021 Conference

Quotient Sciences will be attending the Biopharm America Conference from September 20-23, 2021.

Drug Substance Synthesis and Manufacturing

Tactical deployment of best-in-class synthesis technologies to minimize chemistry costs and move your drug substance supply off the critical path.

Accelerating molecules through to Proof-of-Concept, with an integrated early development program

This webinar highlights how a fully integrated development plan can bring together the needs of the drug product team and the clinical development team.

Solubility Webinar Series

Register today for our solubility focused webinar series taking place on October 21st, 26th, or 28th for our Solubility focused webinar entitled: Accelerated development strategies for poorly soluble molecules

Solubility Webinar October 28th

Register today for our upcoming solubility focused webinar on October 28th.

Pharmaceutical Spray Drying to Overcome Poor Drug Solubility

Overcoming poor drug solubility is a common and challenging task facing the formulation scientist today.

Formulation strategies for poorly soluble molecules - Pharmaceutics and biopharmaceutics considerations

This presentation uses expert insight and case studies to explore formulation and solubility challenges and discuss the best strategies and technologies for advancing poorly soluble molecules, to deliver success.

Solubility Webinar October 26th

Register today for our solubility focused webinar on October 26th.

Solubility Webinar October 21st

Register today for our solubility focused webinar on October 21st.

Maximising Formulation Flexibility in First-in-Human Trials

This edition of OBN’s Digital Event series is being organized in collaboration with Quotient Sciences and will highlight how a fully integrated development plan can bring together the needs of the drug product team and the clinical development team.

The Role of Biopharmaceutics in Early Drug Development

This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.

Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.
We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.